Compare Bristol-Myers Squibb Co (BMY) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Xcel Energy Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.89 (market cap $129.94B), while Xcel Energy Inc trades at $78.41 (market cap $48.51B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.7× Xcel Energy Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | XEL | |
|---|---|---|
Market Cap | $129.94B | $48.51B |
Sector | Health | Utilities |
52-Week High | $65.89 | $83.91 |
52-Week Low | $42.60 | $71.75 |
Enterprise Value | $163.92B | $86.82B |
Dividend Yield | 3.96% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
XEL trades at $78.09, up 1.59% today, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations in Q2 2026 with EPS of $0.93, driven by infrastructure investments. The company maintains solid fundamentals, including a 15.28% net income margin and a $0.59 quarterly dividend, while analyst consensus is bullish with a $93.80 price target.
Outlook is positive due to strong earnings growth and a $60 billion capital plan supporting future expansion, but risks include regulatory pushback and high debt levels. The stock offers stability with a 2.87% dividend yield, though technical resistance near $79 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
